Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study.

ABSTRACT:

Background

With the increasing survival rate and overall lifespan of patients with breast cancer, increased mortality due to cardiovascular causes is a notable concern. Anthracyclines, which are commonly used and effective chemotherapeutic agents for breast cancer, are known for their cardiotoxicity. Existing studies vary in their findings owing to heterogeneous factors such as study population and design, underscoring the need for high-quality evidence to comprehensively examine the risk factors for anthracycline-induced cardiotoxicity. This study compared the incidence of cardiovascular disease, all-cause mortality, and their associated risk factors following adjuvant anthracycline therapy as the initial anticancer treatment, utilizing National Health Insurance claims data for a

SUBMITTER: Lim YC 

PROVIDER: S-EPMC12677787 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature